Senses Disorder TRIZ Cases

Substituted bicyclic heteroaryl compounds modulate kinase activity to treat immune disorders and cancers.

Electrotransfer of a dual-gene DNA construct into ciliary muscle cells sustains protein levels, eliminating frequent intravitreal injections.

N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine inhibits Nox4 activity with high selectivity.

Aqueous ophthalmic dye composition stabilized by water-soluble polyol maintains physiological pH and osmolarity.

7-phenoxychroman carboxylic acid derivatives inhibit the DP2 receptor, addressing limited therapeutic options for PGD2-mediated allergic diseases.

Segmenting pressure reduction with ONLR-NPC factor replacement addresses neurotrophic loss in glaucoma.

Novel polypeptide compounds act as selective kappa opioid receptor agonists to deliver potent analgesic activity.

A dual thyrointegrin antagonist combines thyroid hormone and integrin antagonism to inhibit angiogenesis.

Engineering oleaginous fungi to sequester pigments in lipid bodies simplifies extraction and boosts productivity compared to chemical synthesis.

Lactobacillus paracasei-derived extracellular vesicles inhibit IL-6 secretion and activate AMPK signaling to reduce retinal degeneration.

A synthetic peptide promotes eukaryotic cell proliferation in culture media.

Humanizing CDR loops reduces immunogenicity while maintaining binding affinity for treating inflammatory disorders.

Segmenting kinase families via substituted indol-5-ol derivatives resolves limited therapeutic agent availability.

Desferrithiocin analogs link carbohydrate moieties via polyethylene glycol to chelate iron, reducing renal toxicity while improving solubility.

Crystalline rapamycin on polymer surfaces enables controlled drug release profiles for targeted therapy applications.

Heterocycle derivatives inhibit histone deacetylase activity to regulate gene expression.

5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives inhibit MET kinase activity through specific structural modifications.

Targeting the EPO natural antisense transcript with antisense oligonucleotides resolves tumor hypoxia and anemia contradictions.

Segmented monoclonal antibodies preemptively neutralize circulating glucagon to prevent receptor-mediated hyperglycemia in diabetic patients.

Composite polymer microspheres release salicylic acid immediately, eliminating the lag period inherent in slower degrading variants.

Cyclo-trans-4-L-hydroxyprolyl-L-serine enhances mucin secretion and promotes ocular tissue repair.

Dichloroacetate and valproate esters of honokiol induce apoptosis in cancer cells while sparing healthy tissue.

A contact lens integrates a riboflavin reservoir and electrode to drive iontophoretic infiltration into the cornea.

Hydrolyzed silk-derived proteins stimulate TGFβ signaling to accelerate wound closure while maintaining stability in aqueous solutions.

Surface-functionalized dendrimer nanoparticles overcome corneal and blood-retinal barriers to deliver genes and drugs to the posterior eye segment.

Chemical serum replaces behavioral reminders by stimulating trigeminal nerve to increase blink rate and stabilize tear film for dry eye relief.

Red blood cells encapsulate therapeutic peptides to promote phagocytosis by liver antigen-presenting cells, inducing specific immune tolerance.

An adeno-associated virus vector delivers a photoreceptor-specific expression construct encoding retinal membrane guanylyl cyclase 1 to restore enzyme activity.

Segmented biodegradable hydrogel implants sustain travoprost release, resolving adherence and bioavailability bottlenecks in glaucoma therapy.

Genetic editing of mesenchymal stem cells resolves insufficient EGF content in exosomes, enabling enhanced wound healing and scar prevention therapies.

Brimonidine reduces systemic absorption by constricting capillaries, extending netarsudil residency time to minimize side effects.

Substituted diazepan compounds antagonize orexin receptors, addressing the lack of specific antagonists for treating sleep and psychiatric disorders.

Topical pergolide eye drops activate dopamine receptors to stimulate corneal nerve fiber density.

Selective TNFR2 antagonists preserve retinal ganglion cell viability while reducing oligodendrocyte loss in glaucoma treatment.

Segmented AAV vectors deliver CRISPR components to reduce toxic RHO protein levels while minimizing immune responses in retinal tissue.

Injectable photo-polymerizable hydrogel forms a biodegradable scaffold upon light exposure to support tympanic membrane tissue regeneration.

Topical angiotensin peptides replace mechanical sutures to accelerate corneal healing and reduce inflammation.

Pyrimidone derivatives inhibit GSK3β kinase activity to stabilize microtubules, reducing tau hyperphosphorylation in neurodegenerative disease models.

Removing direct repeated sequences from aav genomes enables complete encapsidation of rdvcf and rdvcfl genes for gmp manufacturing.

Lentiviral shRNA cassettes targeting HLA and beta-2 microglobulin reduce immunogenicity, preventing graft rejection in incompatible recipients.

Pyridyl and phenyl substituted piperazine-piperidines inhibit CXCR3 activity to treat inflammatory diseases, autoimmune disorders, and graft rejection.

Oil-in-water nanoemulsion with 100 nm globules provides anti-inflammatory activity for ocular surface disorders, eliminating preservative toxicity.

4-cyano-1H-imidazole derivatives selectively inhibit c-fms kinase via localized binding, resolving insufficient selectivity in broad kinase inhibitors.

Quinazoline derivatives disrupt the CXCR4/SDF-1 interaction, addressing insufficient therapeutic effectiveness for cancer and inflammatory diseases.

Retroauricular depot injections treat secretory otitis media by delivering localized anti-inflammatory drugs to the mastoid, avoiding systemic side effects.

Aqueous ophthalmic solution containing a specific copolymer imparts sufficient lubricity to corneal and soft contact lens surfaces.